---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-106312"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2026-09-09T20:10:18+00:00"
generated_at: "2026-09-09T20:13:29.959904+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics appoints Joseph Truitt to board; CNTY-813 IND on track for Q4 2026

## Summary
- Joseph Truitt appointed to board effective Sept 9, 2026; serves as Class I director, term to 2028 annual meeting.
- Truitt is CEO of iECURE; receives initial option grant of 148,000 shares vesting over 36 months and $40,000 annual retainer.
- CNTY-813 iPSC-derived islet replacement for T1D on track for IND submission in Q4 2026 after FDA pre-IND alignment.
- CNTY-308 CD19-targeted CAR-iT therapy expected to enter clinic in 2026; both use Allo-Evasion 5.0 platform.
- Truitt previously CEO of BioSpecifics and Achillion; also chairman of Larimar Therapeutics (LRMR).

## SEC filing metadata
- accession: 0001104659-26-106312
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2026-09-09T20:10:18+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465926106312/0001104659-26-106312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465926106312/tm2625030d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-106312
- JSON: https://secwatch.observer/filing/0001104659-26-106312.json
- Plain text: https://secwatch.observer/filing/0001104659-26-106312.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.